Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

LGBTQ+

Bayer symbol

Bayer drug cuts infusion burden in haemophilia A

Able to provide longer-term protection against bleeding episodes in late-stage trial

- PMLiVE

Servier signs cancer collaboration with Cellectis

Will target leukaemia and five solid tumours

- PMLiVE

Actavis ‘negotiating $25bn acquisition’ of Forest

Generic company reportedly in late-stage takeover talks

- PMLiVE

Senior changes at EMA

New head of IT and chair of committee for advanced therapies

- PMLiVE

MHRA announces senior appointment

Neil McGuire joins as clinical director of medical devices

Define the patient burden in rare diseases

Putting patients and carers at the heart of the value demonstration equation in orphan drugs is key

- PMLiVE

BHF uses LEGO in first aid campaign

Uses toy to promote use of hands-only CPR

Novartis building

Novartis enters PD-1 race via CoStim acquisition

Expands presence in cancer immunotherapies

- PMLiVE

FDA backs BioMarin drug for rare enzyme disorder

Vimizim is first drug approved in US under rare paediatric disease priority review

- PMLiVE

FDA knocks back J&J and Bayer’s Xarelto in ACS

Follows unanimous negative committee vote

- PMLiVE

EFPIA looks to Lilly for head of comms

Pharma trade body hires Liam English

- PMLiVE

What’s holding you back in creating a successful business model?

Don’t get left behind in the race to find a successful new business model in the pharma industry

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links